VBData· 动脉网-最新·· 5 hours agoPickScore77
Hutchmed Outlicenses KRAS-Targeted ATTC Candidate HMPL-A830 to GSK for $110 Million Upfront, Up to $1.295 Billion Total
In brief
Hutchmed has granted GSK exclusive rights to develop and commercialize the candidate HMPL-A830 worldwide outside Greater China. Hutchmed will receive an upfront payment of $110 million and is eligible for up to $1.185 billion in development, regulatory and commercial milestone payments plus tiered sales royalties, for a potential total deal value of up to $1.295 billion.
Why it matters
An early Phase I asset outlicensed for a $110 million upfront, with a KRAS small-molecule payload conjugated to an EGFR antibody offering a differentiated design beyond conventional cytotoxic ADCs.
Source: VBData